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Abstract
Insulin degludec is an ultra-long-acting insulin analogue that is increasingly being used in diabetes due to its favourable efficacy
and safety profile. Thus, there is an increasing demand for a reliable and specific analytical method to quantify insulin degludec
for research, pharmaceutical industry and clinical applications. We developed and validated an automated, high-throughput
method for quantification of insulin degludec in human blood samples across the expected clinical range combining
immunopurification with high-resolution mass spectrometry. Validation was performed according to the requirements of the
US Food and Drug Administration. The method satisfyingly met the following parameters: lower limit of quantification
(120 pM), linearity, accuracy (error < 5%), precision (CV < 7.7%), selectivity, carry-over, recovery (89.7–97.2%), stability
and performance in the presence of other insulin analogues. The method was successfully applied to clinical samples of patients
treated with insulin degludec showing a good correlation with the administered dose (r2 = 0.78). High usability of the method is
supported by the small specimen volume, automated sample processing and short analysis time. In conclusion, this reliable, easy-
to-use and specific mass spectrometric insulin degludec assay offers great promise to address the current unmet need for
standardized insulin analytics in academic and industrial research.
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Introduction
Over 200 million people with diabetes are treated with insulin
and this number continues to increase globally [1]. Nowadays,
synthetic insulin or insulin analogues, which have modified
primary sequences compared with human insulin, have be-
come the standard of diabetes care due to their more
favourable pharmacokinetic profile [2, 3]. Short-acting insulin
analogues are administered to achieve peak insulin levels at
mealtimes, whereas long-acting analogues (also known as
basal insulins) provide a steady release of insulin over longer
periods [3]. Insulin degludec (IDeg, Novo Nordisk,
Bagsvaerd, Denmark) is the most recently developed long-
acting insulin analogue and is a DesB30 human insulin acyl-
ated at the ε-amino group of LysB29 with hexadecandioic
acid via a γ-L-glutamic acid linker [4]. This lipidation leads
to self-aggregation into multi-hexamers after subcutaneous
injection and association with human serum albumin in circu-
lation [4], both contributing to the ultra-long action profile of
IDeg of up to 42 h [4, 5]. Clinically, the flat and stable
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pharmacokinetic profile of IDeg translates into a reduced risk
of hypoglycaemia and increased flexibility for administration
[3, 6, 7] making it a popular agent for diabetes care.
Despite the increasing interest in this ultra-long-acting in-
sulin formulation, the ability to reliably quantify IDeg in hu-
man blood samples currently remains a challenge. Amongst
the widely available immunometric assays for insulin, only
two providers show low to modest cross-reactivity with
IDeg [8]. A commonly cited specific IDeg immunoassay
seems to be confined to the manufacturer of the insulin for-
mulation [9]. Regardless of their availability, all
immunometric assays are unable to separate different insulin
variants in a sample, suffer from interferences and have limit-
ed linear dynamic ranges [8, 10]. Thus, development of mass
spectrometry–based methods that show better performance in
terms of specificity, selectivity and dynamic range is of high
interest [11, 12]. In this context, mass spectrometric immuno-
assays (MSIA) that couple immunopurification with liquid
chromatography mass spectrometry (LC-MS) are currently
regarded as the most promising approach [12, 13]. Although
quantification of IDeg in human plasma using LC-MS has
been recently demonstrated [14], a comprehensive method
validation that meets the criteria set forth by the US Food
and Drug Administration (FDA), essential for clinical trials,
has not yet been performed. Thus, this work aimed to develop
and validate a MSIA workflow for the quantification of IDeg
in human blood samples that exhibits both ease of use and
high performance.
Materials and methods
Chemicals and reagents
Formic acid, water, acetonitrile, trifluoroacetic acid (LC-MS
grade) and hydrochloric acid solution (0.1 N) were from
Fisher Chemical (Waltham, MA, USA). Leucine enkephalin
acetate salt was from Abcam (Cambridge, UK). Bovine insu-
lin was from Sigma-Aldrich (St. Louis, MO, USA). BupH
modified Dulbecco’s PBS Packs (PBS), 10 mM PBS
(pH 7.4), n-octyl-β-D-glucopyranoside (NOG), Nunc
2.0 mL DeepWell plates, Nunc 96-well polypropylene plates
and 500 μL insulin MSIA D.A.R.T.’S (Disposable
Automation Research Tips) 96-rack were from Thermo
Scientific (Tempe, AZ, USA). Bovine serum albumin (BSA)
(Fraction V, cold ethanol precipitated) was from Fisher
BioReagents (Waltham, MA, USA). For calibrants and qual-
ity control (QC), insulin-free, charcoal-stripped, delipidized
human serum was from Cone Bioproducts (Seguin, TX,
USA). For selectivity assessment, serum and plasma from
the following sources were tested: sodium EDTA (pooled)
plasma, potassium EDTA (pooled) plasma and serum
(pooled) from BioIVT (Hicksville, NY, USA); sodium
heparin plasma (pooled) from ProMedDx (Norton, MA,
USA); stripped human serum (non-pooled) from Biocell
(Rancho Dominguez, CA, USA). All insulin formulations
were purchased from the Hospital Pharmacy: IDeg and insulin
aspart (IAsp) were from Novo Nordisk Pharma (Bagsvaerd,
Denmark). Insulin glulisine (IGlu) and insulin lispro (ILisp)
were from Sanofi-Aventis (Gentilly, France).
Clinical samples
Fasting EDTA plasma samples were collected from 14 male
adults with type 1 diabetes (age 31 ± 8 years, body mass index
25.6 ± 3.2 kg/m2) treated with basal IDeg. Patients provided
written informed consent and sample collection was approved
by the local Ethics Committee (2018-02070). All patients
were at a stable IDeg regimen and injected 24 ± 9 units of
IDeg (Tresiba U-100, Novo Nordisk Pharma, Bagsvaerd,
Denmark) 8.7 ± 5.0 h before sample collection. Plasma was
separated by centrifugation within 30 min of collection and
stored at − 80 °C until analysis.
Preparation of calibrants and quality control samples
Commercial IDeg was provided at a concentration of 600 μM
and stored at − 20 °C in 20-μL aliquots. Calibrants were pre-
pared by serial dilution in stripped serum at 120, 250, 500,
1000, 2000, 4000, 6000 and 8000 pM. QC samples were at
120 pM (LLOQ), 360 pM (QC low), 1500 pM (QC mid) and
7000 pM (QC high). Concentrations were chosen to cover the
full range of expected therapeutic IDeg levels in patients with
type 1 and type 2 diabetes [5]. Bovine insulin was prepared at
a concentration of 697.7 μM in 0.1 N HCl to be used as an
internal standard (ISTD). In total, 20-μL aliquots were created
for storage at − 20 °C. For each assay, a fresh aliquot was
thawed and serially diluted in 150 nM NOG in 10 mM PBS,
pH = 7.4. For measurement, 250 μL of sample (calibrants, QC
or patient samples) was used. In total, 250 μL of 800 pM
bovine insulin was added to each sample as ISTD. For blank
samples, 250 μL of 10 mM PBS was used instead of serum.
Degludec immunoprecipitation using insulin MSIA
D.A.R.T.’S
IDeg immunoprecipitation from serum samples was achieved
using insulin MSIA D.A.R.T.’S mounted onto a Versette au-
tomated liquid handler (Thermo Scientific, USA) equipped
with a 96 head as previously described with minor variations
[15]. In contrast to the previously published method, only
250 μL instead of 500 μL is used and the following sequence
was used for the automatized immunoprecipitation of IDeg
from serum: MSIA D.A.R.T.’S were initially rinsed with
10 mM PBS, pH 7.4 (20 cycles, 150-μL aspiration/
dispensation volume each). For immunocapture, the serum
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samples were aspirated using the rinsed MSIA D.A.R.T.’S
(100 cycles, 250-μL aspiration/dispensation volume each).
After immunocapture, tips were rinsed twice with PBS
10 mM, pH 7.4 (20 cycles, 150-μL aspiration/dispensation
volume each) and twice with water (20 cycles, 150-μL
aspiration/dispensation volume each) (see Electronic
Supplementary Material (ESM) Table S1). Elution of the
immunoprecipitated insulin was performed in 60 μL of an
acidic solution (100 cycles, 50-μL aspiration/dispensation
volume each) consisting of 0.4% trifluoroacetic acid and
33% acetonitrile containing 450 μg/mL leucine enkephalin
and 25 mg/L BSA to help stabilize eluates post-elution.
Eluates were directly placed in the autosampler for LC-MS
analysis. The total procedure took 1 h and 25 min to be com-
pleted. To verify robustness, MSIA D.A.R.T.’S from three
different lots (19290622, 19300529 and 19401400) were used
during the validation procedure.
Quantification of insulin by liquid chromatography
high-resolution mass spectrometry
Liquid chromatography was performed using a Thermo
Vanquish UHPLC system with a ProSwift RP-4H LC column
1 × 50 mm (both Thermo Scientific, USA) maintained at
70 °C. Solvent A was 0.2% formic acid in water and solvent
B was 0.2% formic acid in acetonitrile. In total, 50 μL of each
extracted sample was injected onto the column with a starting
flow of 150 μL/min and an organic phase (B) gradient at
0 min, 15% and 0.6 min, 15%; after a flow increase to
300 μL, the gradient of the organic phase continued at
0.7 min, 28%; 4.5 min, 35%; 4.6 min, 35%; 4.8 min, 90%;
5.5 min, 90%; 5.7 min, 15%; and 7.4 min, 15%; and finally,
flow was decreased to 150 μL/min with a gradient at
7.5 min, 15%. The autosampler temperature was set to
4 °C. To verify robustness, four different LC columns
from two different lots (Lot 040-15-007 S# 001369 and
001375; Lot 023-15-007 S# 001350 and S# 001371)
were used during the validation procedure.
In contrast to a previously published method [15], both the
change in column and gradient were altered, resulting in an
analysis time reduced by 50%. Note that using this former
method, quantification of IDeg was not possible due to
unfavourable interactions with the stationary phase, most
likely the result of the lipidation of IDeg in comparison
with other insulins.
The chromatographic system was coupled to a Q Exactive
Plus hybrid quadrupole-Orbitrap mass spectrometer (Thermo
Scientific, USA) working in positive ion mode with a spray
voltage of 4.5 kV and an inlet capillary temperature of 300 °C.
The instrument was set to operate in full scan mode acquiring
full scan data MS with a resolution setting of 70,000 (at m/z
200) in a mass range of 1100–1600 Da (AGC target 1e6 and
maximum injection time 200 ms).
Data analysis
The most abundant charge states and the most abundant iso-
topes per each charge state were used for quantification (Fig. 1
and Table 1). The summation of the most abundant isotopes
per each of the 4+ and 5+ charge states was combined to
provide the total AUC (area under the curve) for IDeg and
the bovine insulin used as ISTD. IDeg quantification was
based on a calibration curve generated by plotting the concen-
trations of IDeg versus the ratio of the AUCs of IDeg and
bovine insulin. Mass tolerance of all m/z values was set to
5 ppm. All data were processed using Pinpoint 1.3 and
TraceFinder 4.0 software (Thermo Scientific, USA).
Method validation
The method was validated according to FDA guidelines
for bioanalytical method validation [16] for the follow-
ing parameters: lower limit of quantification (LLOQ),
linearity, accuracy, precision, selectivity/specificity, car-
ry-over, recovery and stability.
Lower limit of quantification
The LLOQ of the assay was calculated analysing replicates
(n = 15) of spiked charcoal–treated serum samples at 120 pM
on three different days spread over 2 weeks. Replicates (n = 2)
of the zero calibrators (blank serum spiked with internal ref-
erence only) were injected in each same run for comparison.
Linearity
Linearity was determined by spiking charcoal-treated serum
(blank matrix) with 120, 250, 500, 1000, 2000, 4000, 6000
and 8000 pM of IDeg in duplicate. A blank (no sample, no
ISTD) and a zero calibrator (blank plus ISTD) in the same
serum matrix were included also in the run. Independent cal-
ibration curves were prepared and analysed on three different
days across 2 weeks.
Accuracy and precision (intra-assay and inter-assay)
The intra-assay accuracy and intra-assay precision of the
method were evaluated by preparing replicates (n = 15) of
QC samples at 120 pM (LLOQ), 360 pM (low), 1500 pM
(mid) and 7000 pM (high). In the same run, a duplicate cali-
bration curve containing the same calibrants as for linearity
(see above) was used to calculate the QC concentrations.
Inter-assay accuracy and inter-assay precision were calculated
based on the replicate determination of each concentration
level made on three separate days spread across 2 weeks
(n = 15 at each concentration and on each day).
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Selectivity/specificity
The selectivity and specificity of the method were tested using
six blank samples from different commercial sources. These
blank matrices were fortified with the insulin analogues IGlu,
IAsp or ILisp to check interference on method performance
from potential concomitant medication. Specifically, the
pooled disodium EDTA plasma and the pooled serum were
spiked with 600 pM of IGlu; the pooled sodium heparin plas-
ma and the dipotassium EDTA plasma were spiked with
600 pM of IAsp and the two non-pooled serums were spiked
with 600 pM of ILisp. The presence of interference at the
retention times of the analyte (IDeg) and internal standard
(bovine insulin) was assessed. The ISTD response in the blank
was also tested to not exceed 5% of the average ISTD re-
sponse of the calibrators and QCs. Additionally, the ability
of the assay to accurately and precisely measure IDeg in the
presence of IGlu, IAsp and ILisp, each spiked at a
Fig. 1 Representative LC-MS data of simultaneous extraction and
detection of insulin degludec and bovine insulin from charcoal-treated
serum spiked at a concentration of 2000 pM. The mass spectra are
averaged across the chromatographic peak. The insets show the isotopic
distributions of the corresponding charge state averaged over the
chromatographic peak. a Insulin degludec 4+ charge state. b Insulin
degludec 5+ charge state. c Bovine insulin 4+ charge state. d Bovine
insulin 5+ charge state
Table 1 m/z values of the ions summed for quantification of insulin
degludec and bovine insulin (theoretical values)
Insulin degludec m/z values Bovine insulin m/z values
4+ 1526.4677 4+ 1433.6582
1526.7182 1433.9088
1526.9687 1434.1593
1527.2191 1434.4097
1434.6601
5+ 1221.3756 5+ 1147.3285
1221.5760 1147.5289
1221.7764 1147.7292
1221.9767 1147.9295
1222.1771 1148.1298
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concentration of 600 pM, was evaluated. This concen-
tration was selected based on expected peak levels of
these rapid analogues in a representative insulin-treated
patient without severe insulin resistance. IDeg QC sam-
ples in replicates of six were prepared at four concen-
tration levels, 120 pM (LLOQ), 360 pM (low),
1500 pM (mid) and 7000 pM (high) in the presence
of other analogues at the indicated concentration.
Additionally, QC samples were also prepared in pooled
human serum at concentration levels of 360 pM,
1500 pM and 7000 pM (n = 14 at each concentration)
for the assessment of accuracy and precision in a more
complex matrix (ESM Table S2).
Carry-over
The carry-over was determined by analysing blank samples
(n = 2) after injection of the calibrant at the highest concentra-
tion (8000 pM) on three different days throughout 2 weeks. In
the same batch, replicate analyses (n = 5) of analyte at the
LLOQ of the assay were included for comparison.
Recovery
The reproducibility of the analyte recovery was studied by
analysing five replicate QC samples spiked at three concen-
tration levels, 360 pM (low), 1500 pM (mid) and 7000 pM
(high). These samples were compared to five replicate blank
sample extracts spiked with the same concentrations of the
analyte post-extraction and before LC-MS injection.
Stability
The stability of the analyte in the post-elution preparation
before LC-MS injection was assessed at times 0 h, 24 h and
48 h. For each day, a fresh calibration curve was prepared with
each calibration point in duplicate. Four replicates of QC sam-
ples at two concentration levels, 360 pM (low) and 7000 pM
(high), were tested at each time. Extracted samples were
stored in an LC-MS autosampler at 4 °C for the indicated
times before analysis.
Robustness
Throughout the validation procedure, MSIA D.A.R.T.’S from
three different lots and four different LC columns were used.
Additionally, the accuracy and precision experiments were
performed independently by two different technicians. None
of these parameters had any impact on assay performance.
Results
Our workflow consists of three steps: analytes are ex-
tracted from serum or plasma by immunopurification,
then separated by liquid chromatography and finally de-
tected by mass spectrometry. Representative LC-MS da-
ta is shown in Fig. 1. The internal standard bovine
insulin is eluted at the retention time of 1.7 min, IDeg
after 2.1 min. Due to their different molecular sum for-
mulas, both compounds exhibit different masses and
therefore also compound-specific m/z values are detected
by the mass spectrometer. Due to the highest signal
intensity, the m/z values corresponding to 4+ and 5+
charge states of the analytes were selected for analysis.
These m/z values are listed in Table 1.
We carried out method validation according to the FDA
guidelines on bioanalytical method validation (see
“Materials and methods” for details). The lower limit of quan-
tification (LLOQ) was established at 120 pM (accuracy 7.8–
16% error, precision 2.5–11.3% CV) and linearity was con-
firmed up to a concentration of 8000 pM (r2 = 0.99 for three
independent runs; 95% of all calibrators (n = 70) within ±
15%). Intra-assay accuracy and inter-assay accuracy were
maintained over the entire calibration range: all samples were
within ± 10% of theoretical values (n = 60), thereby clearly
outperforming the target criteria (± 15%; Table 2). Similarly,
intra-assay precision and inter-assay precision were below
10% CV at all tested concentrations (Table 2).
It is crucial for clinical assays to be free of interference, as
characterized by the selectivity and specificity of the method.
Selectivity was confirmed by the absence of signals at the
retention times of IDeg and the internal standard in six inde-
pendent serum and plasma samples. Specificity was investi-
gated in the same samples fortified with commonly used
rapid-insulin analogues (IGlu, IAsp and ILisp) at a clinically
relevant concentration of 600 pM. The first step of our
workflow is unspecific due to the antibody used for
immunopurification: it extracts IDeg as well as the other in-
sulin analogues, IGlu, IAsp and ILisp. Specificity is then in-
troduced by the following LC-MS step: IGlu, IAsp and ILisp
Table 2 Intra- and inter-assay accuracy and precision (n = 15 for each
concentration)
QC concentration (pM)
120 360 1500 7000
Accuracy (error %) Intra-assay − 3.0 0.0 0.0 − 2.0
Inter-assay 5.0 − 1.0 − 2.0 2.0
Precision (CV %) Intra-assay 5.7 6.2 3.9 5.7
Inter-assay 3.8 6.2 5.1 7.7
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display clearly different retention times compared with IDeg
and all analytes have different mass values, and therefore dif-
ferent m/z values are detected by the mass spectrometer; con-
sequently, the measurement of IDeg is not interfered by these
compounds (Fig. 2). Lack of interference was also confirmed
in clinical samples (Fig. 3).
Moreover, we evaluated whether the presence of IGlu,
IAsp or ILisp at 600 pM has an effect on accuracy and preci-
sion for the measurement of IDeg (Table 3). Except for the
lowest tested IDeg concentration (120 pM) for which accura-
cy was in the range of 25% error, accuracy and precision were
maintained at the other IDeg concentrations (360, 1500 and
7000 pM; see Table 3). Note that low IDeg level of 120 pM
reflects an unlikely clinical scenario given that reported
steady-state concentrations of IDeg are consistently between
3000 and 8000 pM at doses between 0.4 and 0.8 U/kg body
weight independent of age groups [5]. To verify robustness
and lack of matrix effect, a set of QC samples was prepared in
pooled human serum. The results presented in Table S2 (see
ESM) clearly show that accuracy and precision are still main-
tained in this real-world matrix and that parallel detection of
endogenous insulin is feasible (ESM Fig. S1).
Finally, carry-over (4% of the LLOQ signal), recovery
(89.7–97.2%) and stability (accuracy 9.1% error, precision
< 8.2% CV) (Table 4) were also confirmed to be within the
limits defined by the FDA guidelines.
Applicability of the method was tested in clinical samples
of patients with type 1 diabetes using IDeg at an average dose
of 0.3 U/kg body weight. Mean ± SD concentrations of 3035
± 1238 pM (n = 12) were found and we observed a positive
correlation (r2 = 0.78, p < 0.001) between the administered
IDeg dose and measured IDeg blood levels (Fig. 4) in line
with previous reports [5].
Discussion
In the present work, we developed and validated an automat-
ed, high-throughput method for quantification of IDeg in hu-
man blood samples by combining immunopurification
with liquid chromatography high-resolution mass spec-
trometry. The novel method satisfyingly met the FDA
criteria by showing adequate accuracy, specificity and
linearity covering the range of expected therapeutic
IDeg concentrations in human samples.
Compared with other LC-MS-based methods for insulin
quantification [12], the present approach uses a small sample
volume of 250 μL and includes a simple and automated sam-
ple preparation, both contributing to its high usability. Thanks
to its ease of use and rapid run time (7.5 min per sample or
12 h to run a 96-well plate), the method is highly suitable for
studies with a large number of blood samples such as phar-
macokinetic studies. The need for reliable and standardized
insulin analytics to support the performance of pharmacoki-
netic studies becomes particularly evident in view of the re-
cent and upcoming expiration of patent protection for a num-
ber of insulin preparations. This will open up the insulin mar-
ket worldwide to manufacturers of insulin generics or
biosimilars [17–19]. Demonstration of pharmacokinetic
equivalence will be a central part of the approval pathway.
Additionally, a number of novel devices targeting minimally
invasive insulin delivery at high precision will require in vivo
validation studies with accurate insulin quantification [20],
especially in view of the new Medical Device Regulation
coming into force in May 2021 in Europe [21].
Fig. 2 Extracted ion chromatograms (four most abundant isotopes of the
5+ charge state for each compound) of human serum spiked with the
insulin analogues glulisine, lispro and aspart at 600 pM each. The
extracted ion chromatogram of degludec is the sum of the
measurements of the other insulin analogues. The absence of a peak in
the top panel demonstrates that none of the other analogues causes
interference with the degludec measurement. Besides having different
mass and therefore m/z values, the other insulin analogues also display
clearly different retention times compared with degludec
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Despite the many clinical benefits of IDeg and hence
increasing popularity, the underlying complex biochem-
ical structure poses challenges to its measurement.
Commercial immunoassays for human insulin show lim-
ited use for IDeg and the presence of a fatty acid mod-
ifies its chromatographic behaviour compared with other
insulin analogues, thereby affecting the performance of
LC-MS-based insulin assays [14]. In the present work,
chromatographic conditions were therefore carefully op-
timized to circumvent this issue while still keeping anal-
ysis time short.
Due to the fact that IDeg is often co-administered with
rapid-acting insulin analogues (IGlu, IAsp and ILisp), we en-
sured that the assay also shows adequate performance in the
presence of these agents at clinically relevant therapeutic con-
centrations. Besides having different mass and m/z values,
these other insulin analogues also display clearly different
retention times to IDeg. The capacity of multiplexing different
types of insulin within a single sample measurement will pave
the way towards more complex investigations simultaneously
exploring pharmacokinetics of IDeg and other insulin ana-
logues in patients using combination regimens.
We acknowledge that our work is not without limitations.
First, IDeg and the other insulin analogues have been assessed
in vitro using the parent drug. However, reference standards
are not widely available, nor are isotopically labelled internal
reference standards. As such, it would be useful for providers
of reference materials to consider the production of insulin
analogues and their degradation products for inclusion into
quantitative workflows such as ours in the future. Second, a
Fig. 3 Extracted ion
chromatograms of degludec (a
and b for the 5+ and 4+ charge
states, respectively) and bovine
insulin (c and d for the 5+ and 4+
charge states, respectively)
extracted from a patient sample.
Dotted lines indicate the peak
maximum of the analytes in
stripped plasma (cf. Fig. 1). Even
in complex clinical samples, no
interference for either compound
is detected
Table 3 Accuracy and precision of degludec in the presence of
additional insulin analogues (n = 6 at each concentration)
QC (pM) 600 pM glulisine 600 pM aspart 600 pM lispro
Accuracy (error %)
120 28.6* 26.6 25.7
360 12.4 − 5.1 − 6.8
1500 − 14.0* − 15.3 − 16.2
7000 − 0.7 − 5.0 − 6.0
Precision (CV %)
120 11.8* 6.9 6.0
360 8.2 5.3 6.0
1500 10.2* 4.0 7.2
7000 8.4 5.7 4.4
*n = 5
Table 4 Degludec stability after elution and before injection into the
instrument
Autosampler storage time 0 h 24 h 48 h
QC (pM) 360 7000 360 7000 360 7000
Accuracy (error %) − 5.5 0.3 − 9.1 − 1.1 2.7 − 2.1
Precision (CV %) 5.4 0.5 6.6 4.1 4.6 8.2
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comprehensive assessment of the assay’s multiplex capacity
and performance warrants further experiments, particularly
the inclusion of the full concentration range of rapid-acting
insulin analogues and human insulin.
In conclusion, the increasing number of people requir-
ing insulin worldwide, the growing diversity of insulin
formulations on the market and multiple novel insulin de-
livery systems highlight the need for reliable, specific and
high-throughput mass spectrometric approaches to quanti-
fy insulin analogues in human blood samples. The advan-
tageous pharmacokinetic properties of IDeg have turned it
into an attractive drug for clinical use. Still, a bioanalytical
method that allows accurate and robust quantification in
human blood samples was lacking up to now. Within this
study, we introduced a novel, automated, high-throughput
antibody-based affinity capture LC-MS method to quantify
IDeg in clinical specimen lacking up to now. The method
fulfils all FDA validation criteria and, combined with its
ease of use, offers new avenues for academic and industrial
research in the field of diabetes.
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